Google Answers Logo
View Question
 
Q: Tablet/ Pill Production ( Answered 5 out of 5 stars,   1 Comment )
Question  
Subject: Tablet/ Pill Production
Category: Miscellaneous
Asked by: blucken-ga
List Price: $50.00
Posted: 13 Jul 2006 11:00 PDT
Expires: 12 Aug 2006 11:00 PDT
Question ID: 745992
Main Question:
How many tablets/ pills are produced annually in the US?
This would include pharma based drugs (generic and branded), OTC
(other the counter drugs) and supplements/ vitamins (nutraceuticals).

Number of pills would be great - value of the pills also would be nice.

Also - bonus information would include what percent are specifially
colored/ branded with a color or other effect.

Clarification of Question by blucken-ga on 13 Jul 2006 11:24 PDT
Would like the same info for Europe - will add tip. Thanks

Request for Question Clarification by czh-ga on 17 Jul 2006 16:58 PDT
Hello blucken-ga,

I?m not posting an answer here since I haven?t been able to find
answers to all elements of your question. I've posted what I've been
able to find in the Comments section below. Please let me know if this
will meet your needs. If you don?t think the answer meets your
requirements, please consider repricing your question so that I can
post the information I?ve found as a partial answer.

I look forward to your clarification.

~ czh ~

Clarification of Question by blucken-ga on 19 Jul 2006 09:04 PDT
sounds like the data isnt available - i re-posted your answer for $50

thanks
Answer  
Subject: Re: Tablet/ Pill Production
Answered By: czh-ga on 19 Jul 2006 09:34 PDT
Rated:5 out of 5 stars
 
Hello blucken-ga,

I'm sorry the information you're looking for is not available. Thanks
for accepting my answer at a modified price.

~ czh ~

------------------------------------------------------

Hello blucken-ga,

This has proved to be a very difficult search. The count for how many
pills or tablets are produced annually in the US has proved very
elusive. I haven?t found anything beyond statements asserting that
Americans consume millions/billions of pills. This doesn?t mean that
there isn?t lots of information available about the national and
global pharmaceutical industry and some indications of the volume of
pill production.

The information you?re looking for might be available in the numerous
very high priced market research reports that cover this industry.
Unfortunately, very little of the contents of these reports is
referenced in the business or trade press. I would be happy to provide
you with links to these if you?re interested.


============
SOLID DOSAGE
============

I discovered in the course of my research that the major category for
the medications you?re looking for is ?solid dosage forms/units? and
it includes tablets and capsules of various forms and some new
categories of quick dissolve films.


http://www.fda.gov/cder/guidance/cmc5.pdf 
Drug Product
A drug product is a finished dosage form (e.g., tablet, capsule, or
solution) that contains a drug substance, generally, but not necessarily, in
association with one or more other ingredients [21 CFR 314.3(b)]. A solid
oral dosage form includes tablets, chewable tablets, capsules, and soft
gelatin capsules.

==

http://www.fda.gov/cder/dsm/DRG/drg00201.htm
Data Element Name. Dosage Form.
Description. This standard provides for all drug dosage forms. 

==

http://www.upm.edu.ph/cp/ip/solids.htm
PHARMACEUTICAL SOLID DOSAGE FORMS

Currently, tablets may be considered the most popular dosage form.
There are several types of tablets available commercially, these
include: the Compressed Tablet (CT), Sugarcoated Tablets (SCT), Film
Coated Tablet (FCT), Enteric-Coated Tablet (ECT), Multiple Compressed
Tablet (MCT), Controlled-Release Tablet, Tablets for Solution,
Effervescent Tablet, Compressed Suppositories or Inserts, Buccal and
Sublingual Tablet.


=========================================================
SOLID DOSAGE (PILLS, TABLETS, CAPSULES) PRODUCTION VOLUME
=========================================================

Using a variety of search terms I was able to find information about
tablet/pill production worldwide for specific factories or
manufacturing plants. It seems no one has consolidated this
information into statistics that match your queries. This search
revealed that there are a lot of changes happening in the production
of medicines. One of the biggest trends is the movement to outsourcing
of manufacturing to third world plants, especially China and India.
Here are some sample reports showing the production capacity of newer
plants. If this kind of information is of interest to you, I could
locate more of these.


http://dominoext.novartis.com/NC/NCPrRe01.nsf/9d19c6f07c24d6b9c1256bf1006da9aa/c0f8d00b7deacc4ac1256e9800417ff8?OpenDocument
Sandoz strengthens global production network with three new facilities

Vienna, May 18, 2004 ? Sandoz, the world's second largest supplier of
generic medicines, is expanding its global production network with the
opening of three new plants this month in Poland, India and Romania.
The USD 80 million total investment will boost production capacity by
three billion tablets and capsules, while creating approximately 500
jobs.

==

http://www.sipac.gov.cn/english/news/t20051101_12717.htm
The Most Advanced Capsule Plant Starts Production in SIP

Suzhou Capsugel Ltd., invested by Capsule Division of American Pfizer
Pharmaceuticals Ltd. in Suzhou, is the largest producer of
pharmaceutical capsules in China. On Oct. 28, the new plant built by
SCL on the east of Jinji Lake, SIP, went into operation with annual
output of 14 billion capsules, making SCL the most advanced capsule
producer in the world.

A leader of pharmaceutical capsule producers in the world, the
century-old capsule division of Pflizer Pharmaceuticals Ltd. claims
over 50% of global market share.

==

http://www.blonnet.com/2005/07/02/stories/2005070203280100.htm
Jubilant buys 64 pc stake in US drug co Trinity Labs

Trigen Laboratories manufactures generic dosage forms and has a USFDA
approved manufacturing facility in Maryland, US. It has an annual
production capacity of 650 million tablets and 35 million capsules
that can be enhanced to one billion tablets a year.

==

http://www.blonnet.com/2004/05/20/stories/2004052002610400.htm
Sandoz opens third plant in India

The Kalwe plant has a production capacity of one billion tablets and
capsules per annum and is expected to go on stream next month, he
said. The plant could be scaled-up to produce five billion tablets and
capsules, if required, he added.

==

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-08-2000/0001382681&EDATE=
Schering-Plough to Build Four New Facilities in Singapore; $450
Million (U.S.) Expansion Boosts Investment in Singapore to $750
Million (U.S.)

The $450 million (U.S.) expansion project will bring the company's
total investment in Singapore to approximately $750 million (U.S.),
significantly adding to the Republic's growing life sciences industry.

The oral solid dosage manufacturing facility will produce finished
pharmaceutical products using active ingredients manufactured in the
primary production facility.  The oral solid dosage facility is
expected to manufacture ezetimibe tablets and a combination of
loratadine and montelukast sodium, both of which are the subject of
U.S. joint ventures with Merck & Co., Inc. and undergoing clinical
trials.

==

http://www.the-innovation-group.com/ChemProfiles/Acetylsalicylic%20Acid.htm
Acetylsalicylic Acid    
As of February, 2003, there are no U.S. producers of acetylsalicylic acid.

Rhodia, the leading global aspirin producer, closed the last remaining
acetylsalicylic acid plant in the U.S. in February of this year,
eliminating 20 million pounds of annual capacity. The company
maintains aspirin production units at Saint Fons, France, and Bangpoo,
Thailand.

DEMAND
2001: 23.8 million pounds; 2002: 23.9 million pounds; 2006: 24.3
million pounds, projected. Demand equals production plus imports
(2001: 6.2 million pounds; 2002: 6.8 million pounds) less exports
(2001: 0.9 million pounds; 2002: 0.9 million pounds).

STRENGTH
Aspirin remains a popular drug with 25 percent share of the total OTC
analgesic market.

==

http://www.pharmaceutical-industry.info/modules/pharmaceutical_projects/projects_astrazeneca_vup25caxxpyzc545ek3sme45.html
AstraZeneca Opens New US$37.8 (26) Million Tablets Expansion Facility

==

http://www.pharmabiz.com/article/detnews.asp?articleid=34166 
July 11, 2006 -- DRL to increase production capacity to 10 bn tablets and capsules


============================================================
SOLID DOSAGE (PILLS, TABLETS, CAPSULES) MANUFACTURING MARKET
============================================================

I was able to find some information about the size of the solid dosage
medications market. Lots of additional information is available on
this topic in the expensive market research reports. Please let me
know if you want a selection of the most relevant ones. The table of
contents gives you some hint of how the industry is defined even if it
doesn?t give you the financial figures.


http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=333037
Outsourcing Solid Dosage Manufacturing, Jun 2, 2006

Contract manufacturers expand production capacity, and opportunities
arise in high potency and fast-dissolving formulations. And, the oral
thin film emerges as a dosage form.

Solid-dosage forms represent an established sector in the secondary
manufacturing market. Annual global expenditures for commercial
pharmaceutical manufacturing for finished-dosage forms is estimated at
$83 billion, of which between $8?12 billion is outsourced, according
to industry estimates offered by Patheon, Inc. (Mississauga, ON,
Canada, www.patheon.com/) in its 2005 annual report. Roughly $3
billion is spent on dosage-form development, of which roughly $1
billion is outsourced.


=============================================================
SOLID DOSAGE (PILLS, TABLETS, CAPSULES) FORMS, COLORS, SHAPES
=============================================================

There is quite a bit of information about developments in this area of
your quest. Most pharmaceutical companies are looking for ways to
extend the profitability of their products so they?re looking for new
forms of drug delivery. I?m also including here some information about
pill identification and the importance of color/shape/form for the
branding of medications.


http://asia.pharmtech.com/pharmtechasia/article/articleDetail.jsp?id=321547&searchString=tablets
Orally Disintegrating Tablets, Apr 20, 2006

Over the past three decades, orally disintegrating tablets (ODTs) have
gained much attention as a preferred alternative to conventional oral
dosage forms such as tablets and capsules. An ODT is a solid dosage
form that disintegrates and dissolves in the mouth (either on or
beneath the tongue or in the buccal cavity) without water within 60
seconds or less. The US Food and Drug Administration Center for Drug
Evaluation and Research (CDER) defines in the Orange Book an ODT as "A
solid dosage form containing medicinal substances, which disintegrates
rapidly, usually within a matter of seconds, when placed upon the
tongue"

Recent market studies indicate that more than half of the patient
population prefers ODTs to other dosage forms (6) and most consumers
would ask their doctors for ODTs (70%), purchase ODTs (70%), or prefer
ODTs to regular tablets or liquids (>80%) (7). These responses may, in
part, be attributed to known ODT advantages such as ease of
administration, ease of swallowing, pleasant taste, and the
availability of several flavors (8). ODTs also offer clinical
advantages such as improved safety and, in some cases, improved
efficacy and other broader indications. In addition, several business
needs are driving ODT technology development and the commercialization
of new products such as the need for expanded product lines, improved
life-cycle management, extended patent life, and marketing advantages.

-----

http://asia.pharmtech.com/pharmtechasia/data/articlestandard//pharmtechasia/172006/321547/i3.gif
Table I: Summary of orally disintegrating tablet products on the US market (3, 5).

==

http://en.wikipedia.org/wiki/Tablet
http://en.wikipedia.org/wiki/Excipient

==

http://www.vonl.com/chips/phartab1.htm
http://www.vonl.com/chips/phartab2.htm
http://www.vonl.com/chips/phartab3.htm
Pharmaceutical Dosage Forms: Tablets

==

http://www.colormatters.com/body_pills.html
Taking the Color of Medications Seriously Pharmaceutical Color ? A New Frontier!

==

http://www.drugs.com/pill_identification.html
Pill Identification Wizard

==

http://www.colorcon.com/best/index.htm
The BEST integrated Brand Enhancement System for Tablets enables
companies to produce distinctive, easy-to-recognize tablets with
unique colors, shapes, markings and coatings.

-----

http://www.colorcon.com/best/med_er_fin.pdf
Medical Error Reduction with Distinctive Tablet Designs

==

http://www.answerbag.com/c_view.php/3598
Home  Index  Health & Fitness  Drugs & Medicine  Prescription
drugs  What is this pill?


==============================================
SOLID DOSAGE (PILLS, TABLETS, CAPSULES) TRENDS
==============================================

These articles discuss current trends in solid dosage manufacturing.
They provides information about the key players, industry
consolidation and new developments worldwide.


http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=333037
Outsourcing Solid Dosage Manufacturing, Jun 2, 2006

Industry fundamentals are positive 

Industry players point to several drivers in outsourcing secondary
manufacturing. "Pharmaceutical sales continue to grow," outlines Doug
Ludwig, Patheon's executive vice-president and chief financial
officer, who spoke at a recent investors' conference in late April. He
points to IMS Health's (Fairfield, CT, www.imshealth.com/) projected
five-year compound annual growth rate of 5?8% for the global
pharmaceutical market.

Moreover, "a major trend in the solid-dosage market is the number of
large pharmaceutical companies looking to outsource their solid-dosage
products as a result of rationalizing their own facilities," observes
Terry Novak, business director at DSM Pharmaceuticals, Inc.
(Parsippany, NJ, www.dsm.com/).

"In solid-dosage manufacturing, we see two key trends," explains Colin
Minchom, Patheon's vice-president of pharmaceutical development
services, Canada. "One is toward lower dose, high-potency
formulations, and the second is demand for formulations for poorly
soluble drugs. Our addition of capabilities for high-potency actives
and liquid-fill hard capsules address both of these needs."

Fast-melt technology advances 
Orally disintegrating tablets (ODTs) is another sector gaining
momentum. "Another key trend is the increasing number of products
being developed and commercialized using fast-melt technology," says
DSM's Novak.

The global ODT market (based on ex-factory sales to wholesalers) was
$2.4 billion in 2004 and is expected to reach $3 billion in 2006,
estimates the consultancy Technology Catalysts International (Falls
Church, VA, www.technology-catalysts.com/). The technology is
important in patient groups that may have difficulty swallowing
conventional oral medications such as geriatric and pediatric patients
or in the administration of certain central nervous systems drugs.

Candidates for oral thin-film delivery 
The 2004 global market (based on ex-factory sales to wholesalers) for
OTF technology in pharmaceutical (OTC) and nutraceutical products was
estimated at $25 million, says Technology Catalysts. The market is
projected to increase to $500 million by 2007, conditioned on the
entry of higher revenue-generating OTC products and possibly
prescription drug products entering the market.

==

http://www.contractpharma.com/articles/2006/03/solid-dosage-manufacturing.php
Solid Dosage Manufacturing ? Opportunities abound for solid dose CMSs

Solid dosage may not be as sexy as some of the novel drug delivery
forms of recent years, but they remain far and away the prevalent
dosage form on the market. The contract manufacturing market for them
continues to grow, spurred on partly by new, smaller entrants into the
marketplace, product line extensions, and large Pharma companies? need
to rethink their manufacturing platforms.

?Today, with more solid dose products being based on high active
compounds, the typical dosing regimen for a patient is BID, or one
tablet per day. Large Pharma companies are still tooled to make the
huge batches,  but with high active-based solid dose product, the
manufacturing need is for smaller batches, based on flexible
capabilities and flexible processes. This is where the third-party
producers are aligning their processes.?

 -- Key Drivers
 -- Extending the Market
 -- Brand X (generics)
 -- Money Talks (investments in new plants)

==

http://www.pharmpro.com/ShowPR.aspx?PUBCODE=021&ACCT=0000100&ISSUE=0601&RELTYPE=PR&ORIGRELTYPE=ATO&PRODCODE=0000&PRODLETT=A
Designing For the Future of Continuous Processing

The FDA?s initiative promoting continuous processing systems for the
pharmaceutical industry and its subsequent PAT guidelines are helping
to promote a revolution in solid dosage pharmaceuticals manufacturing
methods and facility design. Promising improved yields, increased
quality control, better inventory management and vast improvements in
lead times by moving from current batch technology toward continuous
manufacturing processes, the FDA has removed the last great roadblock
to innovation in the solid dosage manufacturing industry, Regulatory
Constraint.

The move to process innovation in solid dosage manufacturing is long
overdue. For many years, the solid dosage pharmaceutical industry
enjoyed high profit margins, overall market control and a regulatory
environment that stifled competition, lessening the need to look to
innovative methods to produce their product. In the last five years,
however, the reality of the changing marketplace forced manufacturers
to seek out ways to better compete, retain profitability, improve
quality and continue to increase shareholder returns.

An ongoing study by O?Neal?s Advanced Technology Research Group
confirms that new solid dosage facilities will be much smaller, cost
less to construct and require much less labor and energy to operate at
current production levels.

==

http://www.frost.com/prod/servlet/report-brochure.pag?id=A918-01-00-00-00
Global Pharmaceutical Contract Manufacturing Markets

Cost Pressure and Need for Greater Productivity Fuel Market Growth
The global pharmaceutical industry is witnessing rapid advances in
processes and technology, and automation is emerging an integral part
of most manufacturing processes. With stricter regulatory norms and
spiraling costs, pharmaceutical companies are opting to outsource
their manufacturing process to contract manufacturing organizations
(CMOs) in order to improve efficiency and productivity.

The pharmaceutical contract manufacturing market is moving beyond
providing traditional services, and is focusing on tapping the large
demand for specialized niche technologies. CMOs have been building
state-of-the-art facilities that rival those of pharmaceutical
companies and are constantly upgrading them to enable novel
manufacturing processes.

Pharmaceutical companies are increasingly adopting the concept of
?virtual pharma?, wherein they retain the marketing rights while
outsourcing all manufacturing activities and related processes. This
allows companies to deliver goods to the market at a faster rate than
an internal plant would allow.

"Among the dosage forms, solid dosage forms are continuing to lead
revenue contribution, whereas liquid dosage forms are expected to lose
their market share to injectables that primarily include sterile
products and biopharmaceuticals (primarily oncology)."

==

http://www.libraries.psu.edu/business/industryguides/pharmaceutical.htm
Pharmaceutical and Medicine Manufacturing Industry -- NAICS 3254 



Blucken-ga, I hope that the information I?ve found will be useful. If
you need additional information based on my findings I?ll be happy to
continue the search. Please let me know if I can post this as an
official answer.

All the best.

~ czh ~
blucken-ga rated this answer:5 out of 5 stars

Comments  
Subject: Re: Tablet/ Pill Production
From: czh-ga on 17 Jul 2006 17:01 PDT
 
Hello blucken-ga,

This has proved to be a very difficult search. The count for how many
pills or tablets are produced annually in the US has proved very
elusive. I haven?t found anything beyond statements asserting that
Americans consume millions/billions of pills. This doesn?t mean that
there isn?t lots of information available about the national and
global pharmaceutical industry and some indications of the volume of
pill production.

The information you?re looking for might be available in the numerous
very high priced market research reports that cover this industry.
Unfortunately, very little of the contents of these reports is
referenced in the business or trade press. I would be happy to provide
you with links to these if you?re interested.


============
SOLID DOSAGE
============

I discovered in the course of my research that the major category for
the medications you?re looking for is ?solid dosage forms/units? and
it includes tablets and capsules of various forms and some new
categories of quick dissolve films.


http://www.fda.gov/cder/guidance/cmc5.pdf 
Drug Product
A drug product is a finished dosage form (e.g., tablet, capsule, or
solution) that contains a drug substance, generally, but not necessarily, in
association with one or more other ingredients [21 CFR 314.3(b)]. A solid
oral dosage form includes tablets, chewable tablets, capsules, and soft
gelatin capsules.

==

http://www.fda.gov/cder/dsm/DRG/drg00201.htm
Data Element Name. Dosage Form.
Description. This standard provides for all drug dosage forms. 

==

http://www.upm.edu.ph/cp/ip/solids.htm
PHARMACEUTICAL SOLID DOSAGE FORMS

Currently, tablets may be considered the most popular dosage form.
There are several types of tablets available commercially, these
include: the Compressed Tablet (CT), Sugarcoated Tablets (SCT), Film
Coated Tablet (FCT), Enteric-Coated Tablet (ECT), Multiple Compressed
Tablet (MCT), Controlled-Release Tablet, Tablets for Solution,
Effervescent Tablet, Compressed Suppositories or Inserts, Buccal and
Sublingual Tablet.


=========================================================
SOLID DOSAGE (PILLS, TABLETS, CAPSULES) PRODUCTION VOLUME
=========================================================

Using a variety of search terms I was able to find information about
tablet/pill production worldwide for specific factories or
manufacturing plants. It seems no one has consolidated this
information into statistics that match your queries. This search
revealed that there are a lot of changes happening in the production
of medicines. One of the biggest trends is the movement to outsourcing
of manufacturing to third world plants, especially China and India.
Here are some sample reports showing the production capacity of newer
plants. If this kind of information is of interest to you, I could
locate more of these.


http://dominoext.novartis.com/NC/NCPrRe01.nsf/9d19c6f07c24d6b9c1256bf1006da9aa/c0f8d00b7deacc4ac1256e9800417ff8?OpenDocument
Sandoz strengthens global production network with three new facilities

Vienna, May 18, 2004 ? Sandoz, the world's second largest supplier of
generic medicines, is expanding its global production network with the
opening of three new plants this month in Poland, India and Romania.
The USD 80 million total investment will boost production capacity by
three billion tablets and capsules, while creating approximately 500
jobs.

==

http://www.sipac.gov.cn/english/news/t20051101_12717.htm
The Most Advanced Capsule Plant Starts Production in SIP

Suzhou Capsugel Ltd., invested by Capsule Division of American Pfizer
Pharmaceuticals Ltd. in Suzhou, is the largest producer of
pharmaceutical capsules in China. On Oct. 28, the new plant built by
SCL on the east of Jinji Lake, SIP, went into operation with annual
output of 14 billion capsules, making SCL the most advanced capsule
producer in the world.

A leader of pharmaceutical capsule producers in the world, the
century-old capsule division of Pflizer Pharmaceuticals Ltd. claims
over 50% of global market share.

==

http://www.blonnet.com/2005/07/02/stories/2005070203280100.htm
Jubilant buys 64 pc stake in US drug co Trinity Labs

Trigen Laboratories manufactures generic dosage forms and has a USFDA
approved manufacturing facility in Maryland, US. It has an annual
production capacity of 650 million tablets and 35 million capsules
that can be enhanced to one billion tablets a year.

==

http://www.blonnet.com/2004/05/20/stories/2004052002610400.htm
Sandoz opens third plant in India

The Kalwe plant has a production capacity of one billion tablets and
capsules per annum and is expected to go on stream next month, he
said. The plant could be scaled-up to produce five billion tablets and
capsules, if required, he added.

==

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-08-2000/0001382681&EDATE=
Schering-Plough to Build Four New Facilities in Singapore; $450
Million (U.S.) Expansion Boosts Investment in Singapore to $750
Million (U.S.)

The $450 million (U.S.) expansion project will bring the company's
total investment in Singapore to approximately $750 million (U.S.),
significantly adding to the Republic's growing life sciences industry.

The oral solid dosage manufacturing facility will produce finished
pharmaceutical products using active ingredients manufactured in the
primary production facility.  The oral solid dosage facility is
expected to manufacture ezetimibe tablets and a combination of
loratadine and montelukast sodium, both of which are the subject of
U.S. joint ventures with Merck & Co., Inc. and undergoing clinical
trials.

==

http://www.the-innovation-group.com/ChemProfiles/Acetylsalicylic%20Acid.htm
Acetylsalicylic Acid    
As of February, 2003, there are no U.S. producers of acetylsalicylic acid.

Rhodia, the leading global aspirin producer, closed the last remaining
acetylsalicylic acid plant in the U.S. in February of this year,
eliminating 20 million pounds of annual capacity. The company
maintains aspirin production units at Saint Fons, France, and Bangpoo,
Thailand.

DEMAND
2001: 23.8 million pounds; 2002: 23.9 million pounds; 2006: 24.3
million pounds, projected. Demand equals production plus imports
(2001: 6.2 million pounds; 2002: 6.8 million pounds) less exports
(2001: 0.9 million pounds; 2002: 0.9 million pounds).

STRENGTH
Aspirin remains a popular drug with 25 percent share of the total OTC
analgesic market.

==

http://www.pharmaceutical-industry.info/modules/pharmaceutical_projects/projects_astrazeneca_vup25caxxpyzc545ek3sme45.html
AstraZeneca Opens New US$37.8 (26) Million Tablets Expansion Facility

==

http://www.pharmabiz.com/article/detnews.asp?articleid=34166 
July 11, 2006 -- DRL to increase production capacity to 10 bn tablets and capsules


============================================================
SOLID DOSAGE (PILLS, TABLETS, CAPSULES) MANUFACTURING MARKET
============================================================

I was able to find some information about the size of the solid dosage
medications market. Lots of additional information is available on
this topic in the expensive market research reports. Please let me
know if you want a selection of the most relevant ones. The table of
contents gives you some hint of how the industry is defined even if it
doesn?t give you the financial figures.


http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=333037
Outsourcing Solid Dosage Manufacturing, Jun 2, 2006

Contract manufacturers expand production capacity, and opportunities
arise in high potency and fast-dissolving formulations. And, the oral
thin film emerges as a dosage form.

Solid-dosage forms represent an established sector in the secondary
manufacturing market. Annual global expenditures for commercial
pharmaceutical manufacturing for finished-dosage forms is estimated at
$83 billion, of which between $8?12 billion is outsourced, according
to industry estimates offered by Patheon, Inc. (Mississauga, ON,
Canada, www.patheon.com/) in its 2005 annual report. Roughly $3
billion is spent on dosage-form development, of which roughly $1
billion is outsourced.


=============================================================
SOLID DOSAGE (PILLS, TABLETS, CAPSULES) FORMS, COLORS, SHAPES
=============================================================

There is quite a bit of information about developments in this area of
your quest. Most pharmaceutical companies are looking for ways to
extend the profitability of their products so they?re looking for new
forms of drug delivery. I?m also including here some information about
pill identification and the importance of color/shape/form for the
branding of medications.


http://asia.pharmtech.com/pharmtechasia/article/articleDetail.jsp?id=321547&searchString=tablets
Orally Disintegrating Tablets, Apr 20, 2006

Over the past three decades, orally disintegrating tablets (ODTs) have
gained much attention as a preferred alternative to conventional oral
dosage forms such as tablets and capsules. An ODT is a solid dosage
form that disintegrates and dissolves in the mouth (either on or
beneath the tongue or in the buccal cavity) without water within 60
seconds or less. The US Food and Drug Administration Center for Drug
Evaluation and Research (CDER) defines in the Orange Book an ODT as "A
solid dosage form containing medicinal substances, which disintegrates
rapidly, usually within a matter of seconds, when placed upon the
tongue"

Recent market studies indicate that more than half of the patient
population prefers ODTs to other dosage forms (6) and most consumers
would ask their doctors for ODTs (70%), purchase ODTs (70%), or prefer
ODTs to regular tablets or liquids (>80%) (7). These responses may, in
part, be attributed to known ODT advantages such as ease of
administration, ease of swallowing, pleasant taste, and the
availability of several flavors (8). ODTs also offer clinical
advantages such as improved safety and, in some cases, improved
efficacy and other broader indications. In addition, several business
needs are driving ODT technology development and the commercialization
of new products such as the need for expanded product lines, improved
life-cycle management, extended patent life, and marketing advantages.

-----

http://asia.pharmtech.com/pharmtechasia/data/articlestandard//pharmtechasia/172006/321547/i3.gif
Table I: Summary of orally disintegrating tablet products on the US market (3, 5).

==

http://en.wikipedia.org/wiki/Tablet
http://en.wikipedia.org/wiki/Excipient

==

http://www.vonl.com/chips/phartab1.htm
http://www.vonl.com/chips/phartab2.htm
http://www.vonl.com/chips/phartab3.htm
Pharmaceutical Dosage Forms: Tablets

==

http://www.colormatters.com/body_pills.html
Taking the Color of Medications Seriously Pharmaceutical Color ? A New Frontier!

==

http://www.drugs.com/pill_identification.html
Pill Identification Wizard

==

http://www.colorcon.com/best/index.htm
The BEST integrated Brand Enhancement System for Tablets enables
companies to produce distinctive, easy-to-recognize tablets with
unique colors, shapes, markings and coatings.

-----

http://www.colorcon.com/best/med_er_fin.pdf
Medical Error Reduction with Distinctive Tablet Designs

==

http://www.answerbag.com/c_view.php/3598
Home  Index  Health & Fitness  Drugs & Medicine  Prescription
drugs  What is this pill?


==============================================
SOLID DOSAGE (PILLS, TABLETS, CAPSULES) TRENDS
==============================================

These articles discuss current trends in solid dosage manufacturing.
They provides information about the key players, industry
consolidation and new developments worldwide.


http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=333037
Outsourcing Solid Dosage Manufacturing, Jun 2, 2006

Industry fundamentals are positive 

Industry players point to several drivers in outsourcing secondary
manufacturing. "Pharmaceutical sales continue to grow," outlines Doug
Ludwig, Patheon's executive vice-president and chief financial
officer, who spoke at a recent investors' conference in late April. He
points to IMS Health's (Fairfield, CT, www.imshealth.com/) projected
five-year compound annual growth rate of 5?8% for the global
pharmaceutical market.

Moreover, "a major trend in the solid-dosage market is the number of
large pharmaceutical companies looking to outsource their solid-dosage
products as a result of rationalizing their own facilities," observes
Terry Novak, business director at DSM Pharmaceuticals, Inc.
(Parsippany, NJ, www.dsm.com/).

"In solid-dosage manufacturing, we see two key trends," explains Colin
Minchom, Patheon's vice-president of pharmaceutical development
services, Canada. "One is toward lower dose, high-potency
formulations, and the second is demand for formulations for poorly
soluble drugs. Our addition of capabilities for high-potency actives
and liquid-fill hard capsules address both of these needs."

Fast-melt technology advances 
Orally disintegrating tablets (ODTs) is another sector gaining
momentum. "Another key trend is the increasing number of products
being developed and commercialized using fast-melt technology," says
DSM's Novak.

The global ODT market (based on ex-factory sales to wholesalers) was
$2.4 billion in 2004 and is expected to reach $3 billion in 2006,
estimates the consultancy Technology Catalysts International (Falls
Church, VA, www.technology-catalysts.com/). The technology is
important in patient groups that may have difficulty swallowing
conventional oral medications such as geriatric and pediatric patients
or in the administration of certain central nervous systems drugs.

Candidates for oral thin-film delivery 
The 2004 global market (based on ex-factory sales to wholesalers) for
OTF technology in pharmaceutical (OTC) and nutraceutical products was
estimated at $25 million, says Technology Catalysts. The market is
projected to increase to $500 million by 2007, conditioned on the
entry of higher revenue-generating OTC products and possibly
prescription drug products entering the market.

==

http://www.contractpharma.com/articles/2006/03/solid-dosage-manufacturing.php
Solid Dosage Manufacturing ? Opportunities abound for solid dose CMSs

Solid dosage may not be as sexy as some of the novel drug delivery
forms of recent years, but they remain far and away the prevalent
dosage form on the market. The contract manufacturing market for them
continues to grow, spurred on partly by new, smaller entrants into the
marketplace, product line extensions, and large Pharma companies? need
to rethink their manufacturing platforms.

?Today, with more solid dose products being based on high active
compounds, the typical dosing regimen for a patient is BID, or one
tablet per day. Large Pharma companies are still tooled to make the
huge batches,  but with high active-based solid dose product, the
manufacturing need is for smaller batches, based on flexible
capabilities and flexible processes. This is where the third-party
producers are aligning their processes.?

 -- Key Drivers
 -- Extending the Market
 -- Brand X (generics)
 -- Money Talks (investments in new plants)

==

http://www.pharmpro.com/ShowPR.aspx?PUBCODE=021&ACCT=0000100&ISSUE=0601&RELTYPE=PR&ORIGRELTYPE=ATO&PRODCODE=0000&PRODLETT=A
Designing For the Future of Continuous Processing

The FDA?s initiative promoting continuous processing systems for the
pharmaceutical industry and its subsequent PAT guidelines are helping
to promote a revolution in solid dosage pharmaceuticals manufacturing
methods and facility design. Promising improved yields, increased
quality control, better inventory management and vast improvements in
lead times by moving from current batch technology toward continuous
manufacturing processes, the FDA has removed the last great roadblock
to innovation in the solid dosage manufacturing industry, Regulatory
Constraint.

The move to process innovation in solid dosage manufacturing is long
overdue. For many years, the solid dosage pharmaceutical industry
enjoyed high profit margins, overall market control and a regulatory
environment that stifled competition, lessening the need to look to
innovative methods to produce their product. In the last five years,
however, the reality of the changing marketplace forced manufacturers
to seek out ways to better compete, retain profitability, improve
quality and continue to increase shareholder returns.

An ongoing study by O?Neal?s Advanced Technology Research Group
confirms that new solid dosage facilities will be much smaller, cost
less to construct and require much less labor and energy to operate at
current production levels.

==

http://www.frost.com/prod/servlet/report-brochure.pag?id=A918-01-00-00-00
Global Pharmaceutical Contract Manufacturing Markets

Cost Pressure and Need for Greater Productivity Fuel Market Growth
The global pharmaceutical industry is witnessing rapid advances in
processes and technology, and automation is emerging an integral part
of most manufacturing processes. With stricter regulatory norms and
spiraling costs, pharmaceutical companies are opting to outsource
their manufacturing process to contract manufacturing organizations
(CMOs) in order to improve efficiency and productivity.

The pharmaceutical contract manufacturing market is moving beyond
providing traditional services, and is focusing on tapping the large
demand for specialized niche technologies. CMOs have been building
state-of-the-art facilities that rival those of pharmaceutical
companies and are constantly upgrading them to enable novel
manufacturing processes.

Pharmaceutical companies are increasingly adopting the concept of
?virtual pharma?, wherein they retain the marketing rights while
outsourcing all manufacturing activities and related processes. This
allows companies to deliver goods to the market at a faster rate than
an internal plant would allow.

"Among the dosage forms, solid dosage forms are continuing to lead
revenue contribution, whereas liquid dosage forms are expected to lose
their market share to injectables that primarily include sterile
products and biopharmaceuticals (primarily oncology)."

==

http://www.libraries.psu.edu/business/industryguides/pharmaceutical.htm
Pharmaceutical and Medicine Manufacturing Industry -- NAICS 3254 



Blucken-ga, I hope that the information I?ve found will be useful. If
you need additional information based on my findings I?ll be happy to
continue the search. Please let me know if I can post this as an
official answer.

All the best.

~ czh ~

Important Disclaimer: Answers and comments provided on Google Answers are general information, and are not intended to substitute for informed professional medical, psychiatric, psychological, tax, legal, investment, accounting, or other professional advice. Google does not endorse, and expressly disclaims liability for any product, manufacturer, distributor, service or service provider mentioned or any opinion expressed in answers or comments. Please read carefully the Google Answers Terms of Service.

If you feel that you have found inappropriate content, please let us know by emailing us at answers-support@google.com with the question ID listed above. Thank you.
Search Google Answers for
Google Answers  


Google Home - Answers FAQ - Terms of Service - Privacy Policy